AstraZeneca: research agreement with Transgene
(CercleFinance.com) - The biotech company Transgene has announced signing a collaborative research agreement with AstraZeneca with exclusive licensing options to jointly develop 5 novel oncolytic immunotherapies, which will be developed based on Transgene's new Invir.
IO platform.
AstraZeneca will select the transgenes to be encoded within the virus and will be responsible for further in-vivo pre-clinical development and, subject to option exercise, clinical development and commercialization of these novel oncolytic immunotherapies.
The agreement provides for the payment of 10 million dollars to Transgene on the signature, plus up to 3 million dollars for preclinical milestone payments, as well as other payments in case of the exercise of options.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
IO platform.
AstraZeneca will select the transgenes to be encoded within the virus and will be responsible for further in-vivo pre-clinical development and, subject to option exercise, clinical development and commercialization of these novel oncolytic immunotherapies.
The agreement provides for the payment of 10 million dollars to Transgene on the signature, plus up to 3 million dollars for preclinical milestone payments, as well as other payments in case of the exercise of options.
Copyright (c) 2019 CercleFinance.com. All rights reserved.